IACT Health is proud to be part of the research team that is getting positive results in migraine relief from the investigational drug Ubrogepant. In a phase 3 clinical trial that evaluating the efficacy, safety and tolerability of both a 50mg and 100mg dose compared to placebo in a single migraine attack in adults, a significantly greater percent of patients received relief in two hours.
“We are pleased with the favorable results of our ACHIEVE I study, which support the efficacy, safety, and tolerability profile of Ubrogepant. We are confident that Ubrogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist will be an option for the treatment of migraines in adults,” said David Nicholson, Chief Research and Development Officer, Allergan. “Allergan remains committed to identifying, developing and bringing to market therapies that address an unmet need for patients suffering from this debilitating disease.”
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.